We recently published a pooled analysis of two sister phase II trials evaluating anastrozole and fulvestrant as NET in postmenopausal HR+/HER2- breast cancer patients (CARMINA02 and HORGEN trials) [18,19,20]. The gene discussed is ERBB2; the disease is breast carcinoma.